$0.81
-0.01 (-1.20%)
Open$0.83
Previous Close$0.82
Day High$0.83
Day Low$0.81
52W High$1.39
52W Low$0.50
Volume—
Avg Volume36.4K
Market Cap36.31M
P/E Ratio0.70
EPS$1.22
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,266.7% upside
Current
$0.81
$0.81
Target
$11.07
$11.07
$6.75
$11.07 avg
$12.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.29M | 21.09M | 7.77M |
| Net Income | 57.70M | 82.44M | 1.80M |
| Profit Margin | 434.2% | 412.5% | 23.2% |
| EBITDA | -26,078,410 | -39,330,829 | 2.38M |
| Free Cash Flow | — | — | 1.78M |
| Rev Growth | -37.0% | -37.0% | +3.8% |
| Debt/Equity | — | — | 0.84 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |